Clinical features and management of autoimmune hepatitis

World Journal of Gastroenterology

Volumn 14, Issue 21, 2008, Pages 3301-3305

  Krawitt, Edward L ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

Autoimmune hepatitis; Autoimmunity; Chronic hepatitis; Cirrhosis; Liver disease

Indexed keywords

ACTIN ANTIBODY; ALPHA FETOPROTEIN; ANTILIVER KIDNEY MICROSOME 1; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GLUCOCORTICOID; HERBACEOUS AGENT; HLA ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MERCAPTOPURINE; MICROSOME ANTIBODY; MINOCYCLINE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CHRONIC HEPATITIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG HYPERSENSITIVITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GRAFT SURVIVAL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; OFF LABEL DRUG USE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; QUALITY OF LIFE; REMISSION; SEROLOGY; SEX DIFFERENCE; SURVIVAL; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

EID: 54349091120     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3301     Document Type: Article

References (38)

1. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-631
2. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-583.
3. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of tyepe 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 523-538.
4. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40:
5. Vergani D, Alvarez F, Bianchi FB,. Cancado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver amtoimmune serology: a consensus statement from the committee for autoimmune serology of the international Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683
6. Frenzel C, Herkel Luth S, Galle PR., Schramm C., Lohse AW. Evaluation of F-actin ELISA for the diagnosis of auto-immune hepatitis. Am J Gastroenterol 2006; 101: 2731-2736
7. Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59: 280-284.
8. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006: 354: 54-66
9. Bridoux-Henno L, Manggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, Reinert P, Bernard O. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2: 825-830.
10. Djilali-Saih I, Renous R, Caillat-Zueman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004; 40: 904-909
11. Strassburg CP, Manns MP. Autoimmune hepatitis in the elderly: what is the difference? J Hepatol 2006; 45: 490-492
12. Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura B, Hiasa Y, Horiike N. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 2007; 5: 255-258.
13. Gassert DJ, Garcia H, Tanaka K, Reinus TF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci 2007; 52: 2433-2437.
14. Samuel D, Riordan S, Strasser S, Kurtovic J, Singh-Grewel I, Koorey D. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol 2004; 2: 622-624
15. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-560
16. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004; 2: 107-112
17. Villalta D, Girolami D, Bidoli E, Bizzaro N, Tampoia M, Liguori M, Pradella M, Tonutti E, Tozzoli R. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 2005; 19: 6-10
18. Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, Bonkovsky HL. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006; 40: 757-761
19. Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 1197-1205
20. Meza-Junco J, Montano-Loza AJ, Martinez-Benitez B, Kimura-Hayama E. Hepatocellular carcinoma in patients with autoimmune liver diseases: two case reports and literature review. Ann Hepatol 2007; 6: 122-126
21. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, de Torres BE, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 9999 (999A): Epub ahead of print
22. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, Vierling J, Zeniya M. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41: 207-215
23. Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003
24. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-591
25. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006; 51: 968-975
26. Tamori A, Shinzaki M, Kosaka S, Hayashi T, Iwai S, Enomoto M, Habu D, Sakaguchi H, Kawada N, Hino M, Shiomi S, Nishiguchi S. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int 2007; 27: 95-100
27. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-1012
28. Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez T, Lopez S, Garsd A, Alvarez F. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43: 635-639
29. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-3236
30. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-809
31. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802
32. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-326
33. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12: 1362-1366
34. Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, Spengler U, Koletzko S, Jansen PL, Hochhaus G, Mollmann Mollmann HW, Prols M, Manns MP. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-934
35. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-1824
36. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl 2007; 13: 966-974
37. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006; 43: 1109-1117
38. Riva S, Sonzogni A, Bravi M, Bertani A, Alessio MG, Candusso M, Stroppa P, Melzi ML, Spada M, Gridelli B, Colledan M, Torre G. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006; 12 573-577